Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.
Important therapeutic principles were established in developing effective enzyme replacement therapy for patients with Gaucher disease. The background and sequence of the investigations that led to effective delivery of exogenous glucocerebrosidase to the lipid-storing macrophages in patients with Gaucher disease are described. The principle of targeting the intravenously injected enzyme to the mannose lectin on the surface of these cells by engineering the glycoform of the enzyme is a useful model of an essential requirement for effective enzyme therapy. Similar strategies are expected to be effective for the treatment of a number of hereditary metabolic disorders of humans.
Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.
R O
RO
Brady
G J
GJ
Murray
N W
NW
Barton
D000328:Adult; D002236:Carbohydrate Conformation; D002240:Carbohydrate Sequence; D002648:Child; D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D008264:Macrophages; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data
D005962:Glucosylceramidase